Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia
Copyright © 2022 Barbot, Mazzeo, Lazzara, Ceccato and Scaroni..
Since the introduction of glucocorticoid (GC) replacement therapy, congenital adrenal hyperplasia (CAH) is no longer a fatal disease. The development of neonatal screening programs and the amelioration of GC treatment strategies have improved significantly life expectancy in CAH patients. Thanks to these achievements, CAH patients are now in their adulthood, but an increased incidence of cardiovascular risk factors has been reported compared to general population in this stage of life. The aim of CAH treatment is to both prevent adrenal insufficiency and suppress androgen excess; in this delicate balance, under- as well as overtreatment might be equally harmful to long-term cardiovascular health. This work examines the prevalence of metabolic features and cardiovascular events, their correlation with hormone levels and GC replacement regimen in CAH patients and focuses on precocious markers to early detect patients at higher risk and new potential treatment approaches.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in endocrinology - 13(2022) vom: 27., Seite 934675 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barbot, Mattia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiovascular risk |
|---|
| Anmerkungen: |
Date Completed 19.08.2022 Date Revised 26.08.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fendo.2022.934675 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344980472 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344980472 | ||
| 003 | DE-627 | ||
| 005 | 20231226024021.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fendo.2022.934675 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1149.xml |
| 035 | |a (DE-627)NLM344980472 | ||
| 035 | |a (NLM)35979433 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barbot, Mattia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.08.2022 | ||
| 500 | |a Date Revised 26.08.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Barbot, Mazzeo, Lazzara, Ceccato and Scaroni. | ||
| 520 | |a Since the introduction of glucocorticoid (GC) replacement therapy, congenital adrenal hyperplasia (CAH) is no longer a fatal disease. The development of neonatal screening programs and the amelioration of GC treatment strategies have improved significantly life expectancy in CAH patients. Thanks to these achievements, CAH patients are now in their adulthood, but an increased incidence of cardiovascular risk factors has been reported compared to general population in this stage of life. The aim of CAH treatment is to both prevent adrenal insufficiency and suppress androgen excess; in this delicate balance, under- as well as overtreatment might be equally harmful to long-term cardiovascular health. This work examines the prevalence of metabolic features and cardiovascular events, their correlation with hormone levels and GC replacement regimen in CAH patients and focuses on precocious markers to early detect patients at higher risk and new potential treatment approaches | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a cardiovascular risk | |
| 650 | 4 | |a congenital adrenal hyperplasia (CAH)–21-alpha hydroxylase deficiency | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a glucocorticoid therapy | |
| 650 | 4 | |a metabolic syndrome | |
| 650 | 4 | |a obesity | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 700 | 1 | |a Mazzeo, Pierluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Lazzara, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccato, Filippo |e verfasserin |4 aut | |
| 700 | 1 | |a Scaroni, Carla |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in endocrinology |d 2010 |g 13(2022) vom: 27., Seite 934675 |w (DE-627)NLM208813357 |x 1664-2392 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:27 |g pages:934675 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fendo.2022.934675 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 27 |h 934675 | ||